TY - JOUR
T1 - Elevated effector cell sensitivity to Treg-cell suppression that is not associated with reduced Th17-cell expression distinguishes HIV + asymptomatic subjects from progressors
AU - Thorborn, Georgina S.
AU - Pomeroy, Laura
AU - Ishohanni, Heidi
AU - Peters, Barry S.
AU - Vyakarnam, Annapurna
PY - 2012/1
Y1 - 2012/1
N2 - Suppression mediated by Treg cells is a balance between Treg-cell suppressive potency versus sensitivity of effector cells to Treg-cell suppression. We assessed if this balance, along with Treg-cell number relative to the Treg-cell counter-regulatory cytokine IL-17, differs between asymptomatic HIV + subjects versus those who progress onto disease. Cross-over studies comparing Treg-cell potency, measured by effector cell proliferation or IFN-γ expression, from HIV-infected versus control subjects to suppress the proliferation of allogeneic control effector cells demonstrated increased sensitivity of CD4 +CD25 - effector cells from asymptomatic HIV + subjects to suppression, rather than an increase in the suppressive potential of their CD4 +CD25 + Treg cells. In contrast, HIV + progressors did not differ from controls in Treg-cell potency or effector cell sensitivity to Treg-cell suppression. Both CD4 +CD25 +Foxp3 + Treg and effector IL-17 absolute cell numbers were significantly lower in all HIV + subjects tested and not restored by antiviral therapy. Thus, these novel data suggest that elevated Treg-cell-mediated suppression due to increased sensitivity of effectors to Treg cells may be a natural host response in chronic asymptomatic HIV infection, which is lost as disease progresses and that this feature of CD25 - effector cells is not inextricably linked to reduced production of the Treg-cell counter-regulatory cytokine IL-17.
AB - Suppression mediated by Treg cells is a balance between Treg-cell suppressive potency versus sensitivity of effector cells to Treg-cell suppression. We assessed if this balance, along with Treg-cell number relative to the Treg-cell counter-regulatory cytokine IL-17, differs between asymptomatic HIV + subjects versus those who progress onto disease. Cross-over studies comparing Treg-cell potency, measured by effector cell proliferation or IFN-γ expression, from HIV-infected versus control subjects to suppress the proliferation of allogeneic control effector cells demonstrated increased sensitivity of CD4 +CD25 - effector cells from asymptomatic HIV + subjects to suppression, rather than an increase in the suppressive potential of their CD4 +CD25 + Treg cells. In contrast, HIV + progressors did not differ from controls in Treg-cell potency or effector cell sensitivity to Treg-cell suppression. Both CD4 +CD25 +Foxp3 + Treg and effector IL-17 absolute cell numbers were significantly lower in all HIV + subjects tested and not restored by antiviral therapy. Thus, these novel data suggest that elevated Treg-cell-mediated suppression due to increased sensitivity of effectors to Treg cells may be a natural host response in chronic asymptomatic HIV infection, which is lost as disease progresses and that this feature of CD25 - effector cells is not inextricably linked to reduced production of the Treg-cell counter-regulatory cytokine IL-17.
KW - HIV
KW - IL-17
KW - Treg cells
UR - http://www.scopus.com/inward/record.url?scp=84855222627&partnerID=8YFLogxK
U2 - 10.1002/eji.201141426
DO - 10.1002/eji.201141426
M3 - Article
C2 - 22002815
AN - SCOPUS:84855222627
SN - 0014-2980
VL - 42
SP - 138
EP - 146
JO - European Journal of Immunology
JF - European Journal of Immunology
IS - 1
ER -